<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1285">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486482</url>
  </required_header>
  <id_info>
    <org_study_id>K032-120</org_study_id>
    <nct_id>NCT04486482</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function</brief_title>
  <official_title>An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleido Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleido Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory, open-label clinical study aims to explore the physiologic effects of KB109,
      a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and
      function in the outpatient setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 to Day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of microbial taxa in fecal samples as assessed by shotgun profiling based on shotgun sequencing.</measure>
    <time_frame>Day 1 to Day 35</time_frame>
    <description>Change from baseline in relative abundance of microbial taxa (operational taxanomic units) in the KB109 + SSC group versus SSC alone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Mild-to-Moderate COVID-19</condition>
  <arm_group>
    <arm_group_label>KB109 + Self Supportive Care (SSC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Self Supportive Care (SSC) Alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>KB109 + Self Supportive Care (SSC)</intervention_name>
    <description>KB109 is a novel glycan</description>
    <arm_group_label>KB109 + Self Supportive Care (SSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Self Supportive Care (SSC) Alone</intervention_name>
    <description>Self Supportive Care (SSC) Alone</description>
    <arm_group_label>Self Supportive Care (SSC) Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be considered for enrollment into this study, each patient must meet all of the
        following Inclusion Criteria:

          1. Be male or female, â‰¥18 years of age

          2. Be willing and able to give informed consent

          3. Screening/Randomization telemedicine visit within 2 days of testing positive test for
             COVID-19

          4. Having self-reported fever or cough for not more than 72 hours prior to COVID-19
             testing

          5. Mild to moderate COVID-19

          6. Able to adhere to the study visit schedule and other protocol requirements

        Patients who meet any of the following Exclusion Criteria at the Randomization Visit will
        not be enrolled into the study:

          1. Patients who are hospitalized for in-patient treatment or currently being evaluated
             for potential hospitalization at the time of informed consent for conditions other
             than COVID-19

          2. History of chronic lung disease

          3. Ongoing requirement for oxygen therapy

          4. Shortness of breath in resting position

          5. Diagnosis of sleep apnea requiring Bilevel Positive Airway Pressure (BIPAP) /
             Continuous Positive Airway Pressure (CPAP)

          6. Female patients who are pregnant, trying to become pregnant or lactating.

          7. Is considered, in the opinion of the PI, to be unlikely for any reason to be able to
             comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kaleido Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <phone>(617) 674-9000</phone>
    <email>clinicalstudies@kaleido.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Balliro, RN,BS,CDE</last_name>
      <phone>617-762-1242</phone>
      <email>cballiro@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Corona Virus</keyword>
  <keyword>Corona Virus Disease</keyword>
  <keyword>Kaleido</keyword>
  <keyword>Kaleido Biosciences</keyword>
  <keyword>KB109</keyword>
  <keyword>Oligosaccharides</keyword>
  <keyword>Glycan</keyword>
  <keyword>Outpatient</keyword>
  <keyword>Pathogens</keyword>
  <keyword>Microbiome Metabolic Therapy</keyword>
  <keyword>MMT</keyword>
  <keyword>Telemedicine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

